# Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas

> **NIH NIH R44** · VENATORX PHARMACEUTICALS, INC. · 2020 · $1,000,000

## Abstract

Project Summary
This 3-year Phase II SBIR Application focuses on advancing the lead “ultra-broad-spectrum” carbapenem
(USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA,
Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired
with a proprietary in-house β-lactamase inhibitor VNRX-5133 (BLI) to protect against resistance by Ambler
Class A, B and D carbapenemase-producing Gram negatives.
In parallel, a discovery effort will be executed to identify a fast follower and/or chemically-diverse back-up
UBSC that could be advanced into IND-enabling studies if required.
Ultimately, it is envisioned that this new combination product will provide a unique clinical option for empiric
therapy of multi-drug resistant polymicrobial infections in the hospital general ward and ICU, and as a second
line therapy for susceptible organisms.

## Key facts

- **NIH application ID:** 9851785
- **Project number:** 5R44AI120392-05
- **Recipient organization:** VENATORX PHARMACEUTICALS, INC.
- **Principal Investigator:** Christopher John Burns
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,000,000
- **Award type:** 5
- **Project period:** 2015-06-15 → 2022-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9851785

## Citation

> US National Institutes of Health, RePORTER application 9851785, Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas (5R44AI120392-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9851785. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*